 | | Vol. 16.02 – 18 January, 2024 |
| |
|
|
| Researcherss conducted a Phase I/II trial of cord blood-derived natural killer cells expressing anti-CD19 chimeric antigen receptor and interleukin-15 in 37 patients with CD19+ B cell malignancies.
[Nature Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators conducted a comparative analysis of multi-omics datasets, comparing embryos resulting from intracytoplasmic sperm injection with those from somatic cell nuclear transfer.
[Nature Communications] |
|
|
|
| Scientists retrospectively analyzed clinical data of 1603 patients who received single-unit cord blood transplantation in eight institutes in Japan between 2000 and 2017. Each human leukocyte antigen (HLA) allele was categorized into 19 supertypes, and the prognostic effect of disparities was then assessed.
[Bone Marrow Transplantation] |
|
|
|
| Surgery was performed on twin-bearing ewes at 88 days, and FGR induced in one twin via single umbilical artery ligation. Melatonin was administered intravenously to a group of ewes commencing on day of surgery until 127 days.
[Pediatric Research] |
|
|
|
| Human umbilical cord MSCs were used, and human umbilical cord MSCs were intervened while making a skin aging model, which was planned to reduce the process of preventing skin aging in the study method.
[Heliyon] |
|
|
|
| Scientists conducted a longitudinal and retrospective analysis and compared the clinical and laboratory manifestations before and after umbilical cord MSC transplantation. The main outcome of the study was overall survival.
[Clinical Rheumatology] |
|
|
|
|
| The authors discuss ex vivo culture protocols for expanding human hematopoietic stem cells and present the results of clinical trials using these techniques, along with future perspectives.
[Cancer Science] |
|
|
|
|
| Elevai Labs, Inc. announced it has signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune Bio, Inc. that grants Elevai a license to use INmune Bio’s proprietary “EMx” technology.
[Elevai Lab, Inc.] |
|
|
|
|
| March 11 – 14, 2024
San Diego, California, United States |
|
|
|
|
|
| | University of Southampton – Southampton, England, United Kingdom |
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| | Guangzhou Institutes of Biomedicine and Health – Guangzhou, China |
|
|
|
| | Cedars-Sinai Board – Anaheim, California, United States |
|
|
|
| | Ottawa Hospital Research Institute – Ottawa, Ontario, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
